ActiGraph Funding: How Much Did They Raise & Key Investors

How Much Did ActiGraph Raise?
Funding & Key Investors

ActiGraph, a prominent player in the medical-grade wearable technology sector, has successfully secured a significant capital injection to bolster its market presence. This latest financing round, which reached $350K, brings the company's cumulative investment to $350K. The infusion of capital underscores the growing demand for high-fidelity physical activity and sleep monitoring solutions within clinical research and pharmaceutical trials.

The strategic backing reflects investor confidence in ActiGraph's ability to scale its proprietary monitoring platforms. By leveraging this recent investment, the firm is well-positioned to accelerate its product development roadmap and expand its footprint in the digital health ecosystem, ensuring that its data-driven insights remain the gold standard for objective health measurement.

What is ActiGraph?

ActiGraph

Manufacturing

Medical Devices & Equipment

Headquartered in Pensacola, Florida, ActiGraph specializes in the design and manufacture of medical-grade wearable devices. The company provides sophisticated hardware and software solutions that enable researchers and clinicians to capture objective, continuous data on physical activity, sleep patterns, and sedentary behavior. Unlike consumer-grade fitness trackers, ActiGraph's technology is engineered for rigorous scientific validation, making it an essential tool for pharmaceutical companies, academic institutions, and clinical research organizations globally. Its market position is defined by a commitment to data integrity and the provision of actionable health metrics that facilitate better patient outcomes and more efficient clinical trial management.

How much funding has ActiGraph raised?

ActiGraph has raised a total of $350K across 1 funding round:

2020

Debt

$350K

Debt (2020): $350K with participation from PPP

Key Investors in ActiGraph

PPP

Public-Private Partnership

What's next for ActiGraph?

With the successful closure of this late-stage financing, ActiGraph is poised to transition into a new phase of operational maturity. The company is expected to prioritize the integration of advanced analytics and machine learning capabilities into its existing monitoring suite, further enhancing the utility of its longitudinal data sets. Furthermore, the strategic allocation of these funds will likely support international market expansion and the strengthening of partnerships within the life sciences sector. As the digital health landscape continues to evolve toward decentralized clinical trials, ActiGraph's focus on high-precision, regulatory-compliant monitoring will be critical in maintaining its competitive advantage and driving long-term value for stakeholders.

See full ActiGraph company page

See More Financial Insights